April 6, 2017 / 10:30 AM / 4 months ago

BRIEF-Achillion announces initiation of patient dosing in phase 2 study of ACH-4471

April 6 (Reuters) - Achillion Pharmaceuticals Inc

* Achillion announces initiation of patient dosing in phase 2 study of ACH-4471 for paroxysmal nocturnal hemoglobinuria

* Achillion Pharmaceuticals Inc - interim results from phase 2 open-label study of ACH-4471 are anticipated during q2 of 2017

* Achillion - look forward to evaluating ACH-4471 in phase 2 trial for patients with C3 glomerulopathy that co plans initiate during H2 of this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below